161 Results

People

  1. Landau
    Landau
  2. Lesokhin
    Lesokhin
  3. Giralt
    Giralt
  4. Hassoun
    Hassoun
  5. Chung
    Chung
  6. Korde
    Korde
  7. Mailankody
    Mailankody
  8. Shah
    Shah
  9. Scordo
    Scordo
  10. Shah
    Shah

Groups

  1. Bone Marrow Transplant (161)
  2. Center for Hematologic Malignancies (161)
  3. Department of Medicine (161)
  4. Hematologic Malignancies Research (161)
  5. Hematologic Malignancies, Division of (161)
  6. Survivorship Research (161)
  7. Myeloma (158)
  8. Epidemiology and Biostatistics (114)
  9. Biostatistics Service (104)
  10. CTCR Scholars (92)
  1. "Hematologic Malignancies Research"
  2. "Heather Landau"
Formats
  1. Meeting Abstract (122)
  2. Journal Article (35)
  3. Research Letter (3)
  4. Correspondence (1)
Groups
  1. Bone Marrow Transplant (161)
  2. Center for Hematologic Malignancies (161)
  3. Department of Medicine (161)
  4. Hematologic Malignancies Research (161)
  5. Hematologic Malignancies, Division of (161)
  6. Survivorship Research (161)

More Groups

People
  1. Heather Landau (161)
  2. Alexander Lesokhin (146)
  3. Sergio Giralt (144)
  4. David Chung (141)
  5. Hani Hassoun (141)
  6. Neha Korde (106)

More People

Years
  1. 2023 (33)
  2. 2022 (28)
  3. 2021 (11)
  4. 2020 (13)
  5. 2019 (8)
  6. 2018 (10)

More Years

Publications
  1. Blood (74)
  2. Clinical Lymphoma, Myeloma and Leukemia (29)
  3. Biology of Blood and Marrow Transplantation (17)
  4. Leukemia and Lymphoma (10)
  5. Bone Marrow Transplantation (5)
  6. Journal of Clinical Oncology (5)

More Publications

Publishers
  1. American Society of Hematology (74)
  2. Elsevier Inc. (49)
  3. Nature Publishing Group (10)
  4. Taylor & Francis Group (10)
  5. American Society of Clinical Oncology (5)
  6. American Association for Cancer Research (4)

More Publishers

Results (161)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma
    Meeting Abstract

    Shah, G.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D.; Gupta, G.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Patel, D.; Tan, C. R.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Meeting Abstract

    Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant
    Meeting Abstract

    Shah, G. L.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D. J.; Gupta, G. K.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save